Exercise program for patients with cardiac amyloidosis
Official title: Pilot Study Evaluating Supervised Cardiac Rehabilitation in Patients With Cardiac Amyloidosis
Run by Wake Forest University Health Sciences · NCT06096675 · Data updated 2026-11-12
This study tests whether a supervised exercise program can help people with cardiac amyloidosis and heart failure feel better and improve their heart health.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Wake Forest University Health Sciences Academic / other |
| Locations | 1 site (Charlotte, North Carolina) |
| Status | Recruiting |
| Started | January 22, 2024 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | July 21, 2026 |
| Trial ID | NCT06096675 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with NYHA Class I-III heart failure who are stable on treatment for cardiac amyloidosis.
✕Probably not a fit
Patients with NYHA Class IV heart failure or significant comorbidities that affect their ability to participate may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effects of a supervised exercise program on patients with cardiac amyloidosis and heart failure with preserved ejection fraction (HFpEF). The Atrium Health cardiac rehabilitation program aims to improve cardiac performance and quality of life through structured exercise sessions. Participants will engage in three one-hour sessions per week for 12 weeks, focusing on enhancing their cardiorespiratory fitness. The study seeks to gather objective data to potentially expand cardiac rehabilitation eligibility for cancer patients in the future.
Why it matters
Potential benefit: If successful, this program could significantly improve the quality of life and cardiac function for patients with cardiac amyloidosis.
How similar studies have gone: Other studies have shown positive outcomes with supervised exercise programs in heart failure patients, suggesting a promising approach for this population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 * New York Heart Association (NYHA) Class I-III Heart Failure * Able to Exercise * On stable treatment for their cardiac amyloidosis or under active surveillance * Life expectancy of at least 6 months * Ability to understand and the willingness to sign a written informed consent document in English, and the willingness/ability to comply with the protocol activities * Participant must be able and willing to follow the cardiac rehabilitation activities Exclusion Criteria: * Inability to provide informed consent * Inability to commit to in-person supervised exercise sessions for three one-hour sessions a week for 12 weeks * NYHA Class IV Heart Failure * Pulmonary disease requiring home oxygen * Gait instability or history of prior falls * In the opinion of the Principal Investigator, have a clinically significant comorbid disease that is likely to affect the ability of the patient to complete the trial, interfere with their ability with measurement of self-reported outcomes.
Where it's running
-
Sanger Heart and Vascular Institute
Charlotte, North Carolina, United States Recruiting
Study contacts
- Principal investigator: Jai Singh, MD — Wake Forest University Health Sciences
- Study coordinator: Dana B Amaro, RN
- Email: Dana.Amaro@atriumhealth.org
- Phone: 704-355-4692
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liver and Coagulation Markers in ATTR Cardiac Amyloidosis
This study tests liver function and blood-clotting markers in people with ATTR-CA to see if they reflect disease severity and progression.
-
Cardiac Amyloidosis: See if Intracardiac Thrombi are Common on CT
This study tests whether a contrast-enhanced cardiac CT can reliably detect intracardiac thrombi in adults with cardiac amyloidosis.
-
Higher pacemaker rate for people with cardiac amyloidosis
This study will see if temporarily increasing the pacemaker rate improves heart-failure symptoms and exercise tolerance in adults with cardiac amyloidosis who already have pacemakers.
-
Using [64Cu]FBP8 PET/MR to find intracardiac blood clots in cardiac amyloidosis
We'll test whether a [64Cu]FBP8 PET/MR scan can find blood clots inside the heart of people with cardiac amyloidosis who have atrial fibrillation or atrial flutter.
-
Chest pain screening for hidden cardiac amyloidosis
We will test whether men over 65 who have chest pain but no coronary artery disease might have hidden cardiac amyloidosis using blood and urine tests, ECG and echocardiography, bone scintigraphy, and sometimes a heart biopsy.
-
Using advanced heart MRI to improve diagnosis and risk prediction for rare cardiomyopathies
This project tests whether advanced cardiac MRI techniques can help diagnose and predict future risk for people with rare heart muscle diseases like Danon, Fabry, cardiac amyloidosis, Noonan syndrome, and cardiac sarcoidosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.